OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
REGN
Regeneron Pharmaceuticals, Inc.
REGN has the edge over OSCR overall, supported by lower modeled downside and stronger modeled upside.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
REGN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Healthy | |
| Strong |
REGN's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over REGN in the historical PE scenario, which offers more potential upside but is not a forecast.
REGN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $951 | — |
| Cheap | 13x | $589 | -38% |
| Fair | 18x | $822 | -14% |
| Current | 21x | $951 | — |
| Expensive | 25x | $1,135 | +19% |
Historical ranges are pointers, not guarantees.
REGN's PE is in its expensive range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
REGN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for REGN, with profitability improving. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
REGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $79.95 | +77% |
| Q3 2026 | $45.21 | +8.1% |
| Q2 2026 | $40.38 | +1.6% |
| Q1 2026 | $40.96 | +4.1% |
| Q4 2025 | $41.48 | +8.2% |
| Q3 2025 | $41.82 | +3.4% |
| Q2 2025 | $39.74 | +5.2% |
| Q1 2025 | $39.34 | +16% |
| Q4 2024 | $38.34 | +10% |
REGN has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over REGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
REGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +36% |
| Q2 2026 | $4.3B | +17% |
| Q1 2026 | $3.6B | +19% |
| Q4 2025 | $3.9B | +2.5% |
| Q3 2025 | $3.8B | +0.9% |
| Q2 2025 | $3.7B | +3.6% |
| Q1 2025 | $3B | -3.7% |
| Q4 2024 | $3.8B | +10% |
REGN's revenue has grown year over year for six quarters in a row: $5.1B last quarter, up 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | +13 points |
| Q2 2026 | 30% | +0.8 points |
| Q1 2026 | 18% | -1.7 points |
| Q4 2025 | 23% | -3.5 points |
| Q3 2025 | 27% | -4.3 points |
| Q2 2025 | 29% | -0.8 points |
| Q1 2025 | 20% | -4.4 points |
| Q4 2024 | 26% | -2.2 points |
REGN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over REGN on cash flow, with more consistent year-over-year improvement.
REGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +4.6% |
| Q2 2026 | $572.8M | -38% |
| Q1 2026 | $848.3M | +4% |
| Q4 2025 | $922M | -13% |
| Q3 2025 | $1.4B | +35% |
| Q2 2025 | $925.4M | +433% |
| Q1 2025 | $815.8M | -41% |
| Q4 2024 | $1.1B | +27% |
REGN still generates free cash flow, though less than at its 2021 peak: $3.8B over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
REGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -400K shares |
| 1 year | -1.5% | -1.6M shares |
| 3 years | -6.9% | -7.8M shares |
| 5 years | -7.3% | -8.3M shares |
| Available history | -7.9% | -9M shares |
REGN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $399.7M |
| Q2 2026 | $1.2B |
| Q1 2026 | $794.3M |
| Q4 2025 | $671.7M |
| Q3 2025 | $664M |
| Q2 2025 | $1.1B |
| Q1 2025 | $1B |
| Q4 2024 | $973M |
REGN spent $3B buying back its own shares over the past year, down 19% from the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over REGN on leverage, with a lower net debt burden relative to earnings.
REGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | -0.2x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Very low |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | -0.1x | Net Cash |
REGN has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
REGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.3 | Neutral |
| Stochastic | 83.3 | Overbought |
REGN's weekly RSI is 69 (neutral) and its Stochastic is 83 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over REGN on valuation relative to its sector.
REGN PE vs Healthcare Sector
| Metric | REGN | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 19% below |
| PE % | 70 | 29 | 41 pts above |
REGN is trading at 21x earnings, a 19% discount to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
REGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $831.1 | 14% above |
| 20 week MA | $783.7 | 21% above |
| 50 week MA | $749.7 | 27% above |
| 100 week MA | $681.9 | 39% above |
| 200 week MA | $782.7 | 22% above |
REGN has climbed back above all five of its weekly moving averages, and it's now 22% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over REGN on returns for 2026, with the stronger performance.
REGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $373.3 | $488.9 | +31% |
| 2021 | $488.9 | $625.4 | +28% |
| 2022 | $625.4 | $726.7 | +16% |
| 2023 | $726.7 | $878.3 | +21% |
| 2024 | $878.3 | $712.4 | -19% |
| 2025 | $712.4 | $785.0 | +10% |
| 2026 YTD | $785.0 | $951.2 | +21% |
REGN has finished higher in five of the last six years. It's up 21% so far in 2026.